医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Acelity to Offer New Gelling Fiber Advanced Wound Dressing

2016年07月28日 PM11:00
このエントリーをはてなブックマークに追加


 

SAN ANTONIO

Acelity, a global advanced wound care and regenerative medicine company, announced today that BIOSORB™ Gelling Fiber Dressing is now available in the United States and has Conformité Européenne (CE) Mark in Europe, where it will be available in the coming months. The BIOSORB™ Dressing is a unique wound dressing that forms a gel when it comes into contact with an exuding wound. This dressing offers increased absorbency and the ability to hold its shape, allowing for intact removal which is designed to make dressing changes less painful for patients. The dressing can be used for a variety of exuding wounds including leg ulcers, pressure ulcers, diabetic foot ulcers, surgical wounds that exude fluid, partial thickness burns, traumatic and oncology wounds.

“The addition of gelling fiber delivers on an important component of our business strategy in that Acelity now has a complete range of advanced wound dressings that will address a full spectrum of patient needs,” said Joe Woody, president and chief executive officer of Acelity. “These dressings, combined with our negative pressure wound technologies form the most comprehensive wound care portfolio offering clinicians around the world healing solutions no matter the acuity or care setting.”

Chronic and surgical wounds affect more than 10.5 million people in the U.S. and Europe and constantly require treatment and attention.1,2 The BIOSORB™ Dressing is a highly absorbent fiber dressing – demonstrated in vitro to have greater absorbency than other leading gelling fibers3 – designed to efficiently manage fluid levels in a variety of wound types. Fiber dressings help keep the wound moist while absorbing excess exudate to limit the chance of maceration, a softening or separation of skin and tissue due to moisture exposure, which can be detrimental to the healing process if left unmanaged.

“The BIOSORB™ Dressing provides an important treatment option for my patients because it leverages gelling fiber technology to help create an optimal environment for wound healing while protecting the wound edge with its increased absorbency, thus supporting the healing process,” said Professor Keith G. Harding, CBE, dean of clinical innovation, Cardiff University, and medical director, Welsh Wound Innovation Centre. “But perhaps even more importantly, the unique construction is designed to minimize pain for patients, a common problem that is critical to address as part of treatment, particularly given that some wounds can last for months or years and require frequent dressing changes.”

BIOSORB™ Gelling Fiber Dressing comprises CMC (carboxymethylcellulose) fibers which allow the dressing to absorb many times its own weight in fluid, protecting the wound edge and surrounding skin. Furthermore, its cellulose fibers reinforce the dressing, allowing it to remain strong and intact when wet. The product is designed to provide ease of application for the clinician, as well as pain-free removal, to create a more comfortable option for patients compared to many other fiber dressings. BIOSORB™ Gelling Fiber Dressing is currently available in the non-silver format (non-antimicrobial), with the silver version (anti-microbial) expected to follow early next year.

About Acelity

Acelity L.P. Inc. and its subsidiaries are a global advanced wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. Available in more than 80 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,800 people around the world.

1 Sen CK, Gordillo GM, Roy S, et al. Human Skin Wounds: A Major and Snowballing Threat to Public Health and the Economy. Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society. 2009;17(6):763-771.

2 Ally, A. (2014). Wound care: An answer to the burden of chronic diseases? Retrieved July 07, 2016, from http://medtechviews.eu/article/wound-care-answer-burden-chronic-diseases

3 Data on file.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160728005983/en/

CONTACT

Acelity
Corporate Communications
Kathryn Skeen, +1-210-882-2067
kathryn.skeen@acelity.com
or
Investor
Relations
Caleb Moore, +1-210-255-6433
caleb.moore@acelity.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • FDA Grants Priority Review for Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
  • TL PLASTIC SURGERY in South Korea, the Best Choice for Your Satisfying Breast Augmentation Surgery
  • Ascendia Pharmaceuticals宣布其治疗急性冠脉综合征的ASD-002项目获颁一项新专利
  • 年次世界患者安全・科学・技術サミットで初めて米国外向けにHDライブストリーミングを実施へ
  • Accelsiors CRO Expands Global Footprint